Device-assessed sleep and physical activity in individuals recovering from a hospital admission for COVID-19: a multicentre study

Tatiana Plekhanova1,2†, Alex V. Rowlands1,2, Rachael A. Evans3,4, Charlotte L. Edwardson1,2††, Nicolette C. Bishop5, Charlotte E. Bolton6,7, James D. Chalmers8, Melanie J. Davies1,2, Enya Daynes2,9, Paddy C. Dempsey1, Annemarie B. Docherty10, Omer Elnemia9, Neil J. Greening9, Sharlene A. Greenwood11,12, Andrew P. Hall11,13, Victoria C. Harris3,4, Ewen M. Harrison10, Joseph Henson1,2, Ling-Pei Ho14,15, Alex Horsley16,17, Linzy Houchen-Wolloff1,16, Kamlesh Khunti1,2, Olivia C. Leavy13, Nazir I. Lone10,19, Michael Marks20,21, Ben Maylor1,2, Hamish J. C. McAuley9, Claire M. Nolan12,23, Krisnah Poinasamy24, Jennifer K. Quint25, Betty Raman26,27, Matthew Richardson3,28, Jack A. Sargeant1,2, Ruth M. Saunders3, Marco Sereno3, Aarti Shikotra2, Amisha Singapuri3, Michael Steiner3,9, David J. Stensel2,5, Louise V. Wain3,13, Julie Whitney29,30, Dan G. Wootton31,32, Christopher E. Brightling3, William D-C. Man33,34, Sally J. Singh3 and Tom Yates1,2 on behalf of Writing group (on behalf of the PHOSP-COVID Collaborative Group)

Abstract

Background: The number of individuals recovering from severe COVID-19 is increasing rapidly. However, little is known about physical behaviours that make up the 24-h cycle within these individuals. This study aimed to describe physical behaviours following hospital admission for COVID-19 at eight months post-discharge including associations with acute illness severity and ongoing symptoms.

Methods: One thousand seventy-seven patients with COVID-19 discharged from hospital between March and November 2020 were recruited. Using a 14-day wear protocol, wrist-worn accelerometers were sent to participants after a five-month follow-up assessment. Acute illness severity was assessed by the WHO clinical progression scale, and the severity of ongoing symptoms was assessed using four previously reported data-driven clinical recovery clusters. Two existing control populations of office workers and individuals with type 2 diabetes were comparators.

Results: Valid accelerometer data from 253 women and 462 men were included. Women engaged in a mean ± SD of 14.9 ± 14.7 min/day of moderate-to-vigorous physical activity (MVPA), with 12.1 ± 1.7 h/day spent inactive and 7.2 ± 1.1 h/day asleep. The values for men were 21.0 ± 22.3 and 12.6 ± 1.7 h /day and 6.9 ± 1.1 h/day, respectively. Over 60% of women and men did not have any days containing a 30-min bout of MVPA. Variability in sleep timing was approximately 2 h in men and women. More severe acute illness was associated with lower total activity and MVPA.
Background
There have been over 330 million confirmed cases of COVID-19 and over 5.5 million deaths [1]. Of the 15.6 million cases in the UK, there have been over 170,000 deaths and > 660,000 patients admitted to hospital [2]. As mortality improves, the number of post-hospitalisation survivors of COVID-19 is increasing. In some studies, more than 70% have not fully recovered by five months after discharge and have a substantial mental and physical health burden [3]. Given this, the pressing need for research to inform and support rehabilitation post-hospitalisation with COVID-19 is evident.

Emerging evidence suggests that physical activity [4, 5], good quality sleep, and regular sleep patterns [5] are associated with lower odds of being admitted to hospital or dying with COVID-19. This may occur through a reduction in chronic inflammation [6, 7] and lower cardiometabolic risk factors, features associated with an increased risk of COVID-19 [8], and/or through enhanced immunity [9]. The ongoing burden of symptoms associated with poor recovery [3] may have a detrimental impact on physical activity and sleep behaviours in post-hospitalisation survivors of COVID-19.

The post-hospitalisation COVID-19 (PHOSP-COVID) study is a large prospective multicentre follow-up study with the aim of understanding and improving long-term health outcomes following COVID-19 (https://phosp.org). Cluster analysis identified four recovery phenotypes relating to the severity of physical, mental, and cognitive health impairments an average of five months post-hospitalisation with COVID-19 [3].

The aim of this study was to describe accelerometer-assessed physical behaviours in patients post-hospitalisation with COVID-19 and to understand whether there are differences in physical behaviours associated with acute illness severity or the four recovery clusters. Physical behaviours within the PHOSP-COVID cohort were also described relative to a cohort of office workers and a cohort of adults with type 2 diabetes.

Methods

Participants and methods
PHOSP-COVID is a prospective longitudinal cohort study recruiting patients aged ≥ 18 years who were discharged from 83 National Health Service (NHS) hospitals across England, Northern Ireland, Scotland, and Wales following admission to a medical assessment or ward for confirmed or clinician-diagnosed COVID-19. Participants were excluded if they: i) had a confirmed diagnosis of a pathogen unrelated to the objectives of this study, ii) attended an accident and emergency department but were not admitted, iii) had another life-limiting illness with life expectancy less than six months. Clinical data collected as part of standard care was obtained from all patients discharged from participating hospitals following participant consent. An additional research visit was offered to all patients from discharge at 3 months (range 2–7 months). The 1077 participants who attended a dedicated research visit within one-year post-discharge were eligible for inclusion [3]. The included participants were assessed at a median five-months (range 2–7 months) between March and November 2020. Recruitment of participants continued until April 2022.

All study participants provided written informed consent. The study was approved by the Leeds West Research Ethics Committee (20/YH/0225) and is registered on the ISRCTN Registry (ISRCTN10980107).

Accelerometer data collection
Physical behaviours (i.e., physical activity and sleep) were assessed using the GENEActiv accelerometer (GENEActiv Original, ActivInsights, Kimbolton, UK). The monitors were initialised to record triaxial accelerations for 21 days at 30 Hz, with participants being asked to wear the monitor for 24 h/day.

Where possible, participants received the monitor and instructions by post within one month of their PHOSP-COVID research visit (2–7 months from discharge). Participants were instructed to start wearing the monitor on their non-dominant wrist immediately upon receiving it and to wear it 24 h/day. Participants were asked to return
their monitors in a prepaid envelope after the 14-day assessment period.

**Accelerometer data processing**

Accelerometer files were processed with R-package GGIR version 2.2–0 (http://cran.r-project.org) [10]. Participants were excluded if they had <3 days of valid wear (defined as ≥16 h/day). Signal processing in GGIR includes auto-calibration using local gravity as a reference; detection of non-wear; calculation of the average magnitude of dynamic acceleration corrected for gravity (Euclidean Norm minus 1 g with negative values rounded up to zero, ENMO), averaged over 5-s epochs and expressed in milli-gravitational units (mg). Non-wear was imputed using the default setting, that is, invalid data were imputed by the average at similar time-points on different days of the week. Participants were excluded if post-calibration error was >0.01 g (10 mg), they had <3 days of valid wear (defined as ≥16 h per day), or if wear data were not present for each 15-min period of the 24-h cycle. Definitions of the physical behaviour variables are shown in the Supplementary material.

Physical behaviour characteristics included average acceleration in mg (a proxy for physical activity volume), moderate-to-vigorous intensity physical activity (MVPA) in minutes accumulated in ≥1-min bouts (>100 mg) [11], light-intensity activity in minutes (between 40 and 100 mg) [12], inactive time (a proxy for sedentary time) in minutes (<40 mg) [12], and intensity of the most active continuous 30 and 10 min/day (mg).

The percentage of participants meeting the guidelines of 150 min per week of MVPA [13] was calculated based on their average daily MVPA (i.e., if >21.4 min/day) and used in analyses as a binary variable.

Weekly physical activity characteristics included the number of days/week with 10- and 30-min continuous MVPA. Weekly variables were limited to participants with at least seven valid days of data.

Sleep characteristics included total sleep time (hours, time between sleep onset and wake time minus any time awake), sleep efficiency (%), and mid-sleep variability (within-person standard deviation of mid-sleep time). Sleep mid-point variability describes how variable people are in the timing of their sleep.

**Disease exposures**

Acute illness severity was determined by the WHO clinical progression scale [14], defined as: i) 3–4= no continuous supplemental oxygen needed, ii) 5= continuous supplemental oxygen only, iii) 6= continuous positive airway pressure ventilation (CPAP), bi-level positive airway pressure (BIPAP) or high flow nasal oxygen, iv) 7–9= invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).

The severity of ongoing symptoms after discharge was categorised on clusters derived previously within PHOSP-COVID where unsupervised machine learning using data from a battery of patient-reported outcomes and physical tests, identified four recovery clusters described as: 1) Very severe mental and physical health impairment, 2) Severe mental and physical health impairment, 3) Moderate mental and physical health impairment with pronounced cognitive impairment, 4) Mild mental and physical health impairment [3]. This outcome is referred to as recovery clusters.

Data for the severity of ongoing symptoms were missing in 27% of included participants due to missing data on the patient-reported outcomes and physical tests used for the cluster analysis [3].

**Covariates**

Data on sex, age at admission, ethnicity, number of chronic diseases, body mass index (BMI), and deprivation were included in this study (Supplementary material).

**Comparative cohorts**

In response to the lack of baseline data for the PHOSP-COVID cohort, the cohort was compared to accelerometer data collected in a cohort of office workers [15] and individuals with type 2 diabetes [16, 17] for descriptive purposes. Details of the comparative cohorts are described in the Supplementary material. Accelerometer data from all three cohorts were processed using identical methods.

**Data selection**

For this analysis, only those with valid accelerometer data were included. Of the 1077 participants in the PHOSP-COVID dataset, postal addresses were available to the research team for 853 participants within one month of follow-up clinical and research data collection visits allowing accelerometers to be posted, of which 796 were returned, with 715 providing valid data (Supplementary Figure S1).

**Statistical analysis**

Differences in physical activity and sleep across acute illness severity and recovery clusters were assessed using generalised linear models. Continuous variables were analysed using a normal distribution with an identity link. Model selection was informed by the Akaike Information Criterion. Although some physical activity variables displayed non-parametric distributions, adjusted model fit was not meaningfully improved using different distribution or log links once covariates were added.
Physical activity bout data was analysed using a Poisson distribution with a log-linear link as count data. Binary logistic regression was used to investigate the odds of not meeting 150 min of MVPA per week across acute illness severity and recovery clusters and reported as odds ratios (95% CI).

Data were adjusted for age at admission, sex, ethnicity, deprivation, number of comorbidities, season of data collection, number of wear days (activity outcomes) or wear nights (sleep outcomes). Interactions between sex and acute illness severity/recovery cluster were included to determine whether differences in physical activity or sleep variables across acute illness severity or recovery clusters varied by sex. Data are reported as sex-stratified marginal means (95% CI) derived from this model.

Generalised linear models were also used to examine associations between the variables that made up the ongoing severity cluster definitions (breathlessness, fatigue, anxiety, depression, post-traumatic stress disorder, physical performance, and cognition—Supplementary material) and physical activity and sleep characteristics. Variables were standardised and analysed as continuous variables. After generating the main effect for each exposure, cluster variable by sex interactions were added to the models and significant interactions were further stratified by sex. Data are reported as beta-coefficients (95% CI).

A sensitivity analysis was conducted, removing healthcare workers to examine whether healthcare work status had an impact on sleep variables.

Data were analysed using SPSS (version 26.0). A $p$-value of $<0.05$ was considered statistically significant.

## Results

Of the 1077 participants included in the PHOSP-COVID dataset, 715 (253 women, 462 men) had valid accelerometer and acute illness severity data. Of these, 521 (185 women, 336 men) also had data for the severity of ongoing symptoms. Participant characteristics are displayed in Table 1. 151 (32.7%) men and 54 (21.3%) women received invasive mechanical ventilation (IMV) during the acute illness (WHO class 7–9), and 172 (37.2%) men and 66 (26.1%) women were classified within the very severe recovery cluster (Supplementary Figure S3). The proportion of the population within the different classifications and clusters of disease severity were similar in those with complete and missing accelerometer data. However, those with complete data were older (59 vs. 55 years), with a higher proportion from White ethnicities (69.8% vs. 58.3%) and the least deprived quintile (20.3% vs. 14.6%).

The summary variables from the accelerometer data for women and men are displayed in Table 1. The median time from discharge to accelerometer wear was 245 days [IQR 178–276 days]. The median time from the PHOSP-COVID research visit to accelerometer wear was 65 days [IQR 11–93 days]. Accelerometer data were available for a mean of 14 valid days. Women engaged in a mean ± SD of 14.9 ± 14.7 min/day of MVPA, with 12.1 ± 1.7 h/day spent inactive and 7.2 ± 1.1 h/day asleep. The same values for men were 21.0 ± 22.3 and 12.6 ± 1.7 h/day and 6.9 ± 1.1 h/day, respectively. Variability in sleep midpoint was ~ 2 h in men and women. Over 60% of both women and men did not have any days in a week that contained a 30-min bout of MVPA, e.g., walking, with most women (56%) also not having any days with a bout of 10-min of MVPA (Table 1).

### Associations with disease severity

Across acute illness severity, those who had the most severe acute illness had ~ 1–2 mg lower volume of physical activity ($p = 0.045$) and less time spent in MVPA ($p = 0.032$) (Table 2). Women who received IMV undertook the lowest levels of MVPA [13.7 min/day; 95% CI 7.3, 20.2] (Table 2). Women and men with the most severe acute disease were 3.38 (95% CI 1.29, 8.85) and 2.17 (95% CI 1.06, 4.45) times more likely, respectively, to not meet physical activity recommendations for health compared to those with the least severe disease (Supplementary Figure S2). The pattern of number of days/week with continuous bouts of MVPA was similar across acute illness severity (Fig. 1).

Across recovery clusters, there was no difference in daily volume of physical activity and time spent in light activity or MVPA (Table 3). However, time spent inactive was greater in men than women ($p = 0.013$), with men in the very severe recovery cluster spending the most time inactive [13.2 h/day; 95% CI 12.6, 13.7]. Men in the severe and the very severe recovery clusters were also 2.52 (95% CI 1.19, 5.36) and 3.48 (95% CI 1.41, 8.59) times more likely, respectively, to not meet physical activity recommendations for health compared to those in the less severe recovery clusters (Supplementary Figure S3).

There was also a notable difference in the number of days/week on which longer bouts of physical activity were undertaken. In the very severe recovery cluster, over 80% of women and men did not undertake a bout of MVPA lasting 30 min on any day of the week, with over 60% not undertaking a bout lasting 10 min on any day (Fig. 2). The frequency of longer bouts of MVPA was substantially higher in those within the mild recovery cluster; over 20% in the mild cluster undertook at least a 10-min bout of MVPA on at least 3 days/week (Fig. 2). Men and women in the severe recovery cluster...
Table 1  Participant characteristics

| Categorical variables | Women (n = 253) | Men (n = 462) |
|-----------------------|-----------------|---------------|
| **WHO disease severity class (acute COVID-19 severity)**<sup>a</sup> | | |
| Class 3–4 | 72 | 28.5% | 67 | 14.5% |
| Class 5 | 89 | 35.2% | 166 | 35.9% |
| Class 6 | 38 | 15.0% | 78 | 16.9% |
| Class 7–9 | 54 | 21.3% | 151 | 32.7% |
| **Recovery cluster** | | |
| Cluster 4: Mild | 38 | 15.0% | 48 | 10.4% |
| Cluster 3: Moderate | 50 | 19.8% | 58 | 12.6% |
| Cluster 2: Severe | 31 | 12.3% | 58 | 12.6% |
| Cluster 1: Very Severe | 66 | 26.1% | 172 | 37.2% |
| Missing | 68 | 26.9% | 126 | 27.3% |
| **Comorbidities** | | |
| No comorbidity | 71 | 28.1% | 134 | 29.0% |
| 1 comorbidity | 53 | 20.9% | 92 | 19.9% |
| 2+ comorbidities | 129 | 51.0% | 236 | 51.1% |
| **Ethnicity** | | |
| White | 175 | 69.2% | 324 | 70.4% |
| South Asian | 32 | 12.6% | 60 | 13.0% |
| Black | 28 | 11.1% | 21 | 4.6% |
| Other | 11 | 4.3% | 32 | 7.0% |
| Missing | 7 | 2.8% | 23 | 5.0% |
| **IMD (quintile)**<sup>b</sup> | | |
| 1 (most deprived) | 37 | 14.7% | 98 | 21.2% |
| 2 | 59 | 23.4% | 107 | 23.2% |
| 3 | 55 | 21.8% | 72 | 15.6% |
| 4 | 46 | 18.3% | 95 | 20.6% |
| 5 (least deprived) | 55 | 21.8% | 90 | 19.5% |
| **Number of days where a 10-min moderate-intensity bout of physical activity was undertaken** | | |
| 0 | 139 | 55.8% | 199 | 44.2% |
| 1 | 48 | 19.3% | 82 | 18.2% |
| 2 | 28 | 11.2% | 58 | 12.9% |
| 3+ | 34 | 13.7% | 111 | 24.7% |
| **Number of days where a 30-min bout of moderate-intensity physical activity was undertaken** | | |
| 0 | 191 | 76.7% | 285 | 63.3% |
| 1 | 33 | 13.3% | 68 | 15.1% |
| 2 | 14 | 5.6% | 45 | 10.0% |
| 3+ | 11 | 4.4% | 52 | 11.6% |
| **Participants meeting > 150 min of moderate-to-vigorous intensity physical activity per week** | | |
| | 68 | 26.9% | 172 | 37.2% |
| **Continuous variables** | | |
| Age (Years) | | |
| | Mean | SD | Mean | SD |
| | 58 | 14 | 60 | 12 |
| BMI (kg/m²)<sup>c</sup> | | |
| | 32.2 | 7.9 | 30.4 | 6.1 |
| Physical activity volume (mg) | | |
| | 19.3 | 6.6 | 19.6 | 7.2 |
| Time spent in moderate or vigorous intensity physical activity (minutes/day) | | |
| | 14.9 | 14.8 | 21.1 | 22.3 |
| Time spent in light intensity physical activity (minutes/day) | | |
| | 149.8 | 54.9 | 138.8 | 51.4 |
| Time spent inactive (hours/day) | | |
| | 12.1 | 1.7 | 12.6 | 1.7 |
| Intensity of the most active 10 min (mg) | | |
| | 61.0 | 39.0 | 73.6 | 64.0 |
| Intensity of the most active 30 min (mg) | | |
| | 40.4 | 25.4 | 49.6 | 47.8 |
| Total sleep time (hours/day) | | |
| | 7.2 | 1.1 | 6.9 | 1.1 |
| Sleep Efficiency (%) | | |
| | 85.7 | 5.2 | 85.0 | 5.7 |
| Variability in sleep midpoint (SD in minutes) | | |
| | 120.5 | 89.5 | 113.4 | 84.9 |
| Number of valid days | | |
| | 14 | 2 | 14 | 2 |
| Number of valid nights | | |
| | 13 | 3 | 13 | 3 |

<sup>a</sup> WHO clinical progression scale: 3–4 = no continuous supplemental oxygen needed, 5 = continuous supplemental oxygen only, 6 = continuous positive airway pressure ventilation (CPAP), bi-level positive airway pressure (BIPAP) or high flow nasal oxygen, 7–9 = invasive mechanical ventilation (IMV) or extra-corporeal membrane oxygenation (ECMO)

<sup>b</sup> IMD = Index of Multiple Deprivation

<sup>c</sup> BMI = body mass index
Table 2 Physical activity and sleep variables across WHO classes of acute illness severity

| Physical activity variables | Women | | | | Men | | | | | | P for class | P for class x sex |
|-----------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Physical activity volume (mg) | 21.3 (19.1, 23.3) | 22.3 (20.4, 24.23) | 19.9 (17.4, 22.4) | 19.8 (17.6, 22.0) | 21.9 (19.8, 24.0) | 22.6 (21.0, 24.2) | 23.3 (21.2, 25.4) | 21.0 (19.3, 22.8) | 0.045 | 0.248 |
| Moderate to vigorous intensity physical activity (minutes/day) | 18.7 (12.9, 24.6) | 19.0 (13.6, 24.5) | 16.0 (8.7, 23.2) | 13.7 (7.3, 20.2) | 25.1 (19.1, 31.1) | 28.5 (23.8, 33.2) | 27.0 (21.1, 33.0) | 21.6 (16.6, 26.7) | 0.032 | 0.783 |
| Light intensity physical activity (minutes/day) | 167.8 (152.0, 183.5) | 171.0 (156.2, 185.7) | 150.2 (130.7, 169.6) | 158.2 (140.7, 175.7) | 154.0 (137.8, 170.2) | 153.8 (141.3, 166.3) | 160.7 (1446, 1769) | 149.1 (135.5, 162.8) | 0.386 | 0.150 |
| Inactivity (hours/day) | 12.0 (11.5, 12.5) | 12.2 (11.8, 12.7) | 12.3 (11.7, 12.9) | 12.5 (12.0, 13.0) | 12.7 (12.2, 13.3) | 12.5 (12.1, 12.9) | 12.5 (12.0, 13.0) | 13.0 (12.5, 13.4) | 0.201 | 0.569 |
| Intensity of the most active continuous 30 min (mg) | 54.6 (42.1, 67.2) | 55.9 (44.2, 67.5) | 47.8 (32.2, 63.3) | 51.7 (38.0, 65.3) | 62.8 (50.0, 75.7) | 66.5 (56.5, 76.5) | 62.9 (50.2, 75.7) | 63.1 (52.2, 73.9) | 0.659 | 0.934 |
| Intensity of the most active continuous 10 min (mg) | 76.8 (59.6, 93.9) | 85.3 (69.3, 101.2) | 71.4 (50.1, 92.6) | 74.7 (56.0, 93.5) | 94.7 (77.1, 1123) | 98.8 (85.2, 112.5) | 96.6 (79.1, 114.1) | 88.5 (73.6, 103.4) | 0.334 | 0.831 |
| Sleep variables | | | | | | | | | | | | | |
| Total sleep time (hours/day) | 70 (66, 73) | 68 (65, 72) | 70 (66, 74) | 67 (64, 71) | 66 (62, 69) | 65 (63, 68) | 65 (62, 68) | 65 (62, 68) | 0.514 | 0.771 |
| Sleep efficiency (%) | 86.8 (85.1, 88.4) | 86.1 (84.6, 87.7) | 85.9 (83.8, 88.0) | 85.8 (84.0, 87.5) | 85.9 (84.3, 87.7) | 85.4 (84.0, 86.7) | 84.8 (83.1, 86.5) | 85.5 (84.0, 86.9) | 0.524 | 0.951 |
| Sleep midpoint variability (minutes) | 918 (661, 1176) | 92.7 (68.7, 1168) | 88.1 (56.4, 1200) | 113.7 (85.4, 1419) | 95.6 (69.1, 122.0) | 91.9 (71.5, 112.3) | 106.9 (80.6, 133.2) | 85.7 (63.5, 108.0) | 0.854 | 0.151 |

Data reported as marginal mean (95% CI). Adjusted for age, sex, ethnicity, deprivation, number of comorbidities, season of data collection and number of wear days (physical activity variables) or wear nights (sleep variables). Models included 675 participants with complete cluster and covariate data.
had the longest total sleep time ($p = 0.039$), with the very severe recovery cluster having the greatest sleep midpoint variability, although this did not reach significance ($p = 0.070$) (Table 3).

Sleep variables across acute illness severity and recovery clusters showed a similar pattern when removing healthcare workers ($N = 98$) (Supplementary Table S2).

The associations of recovery cluster variables with physical activity and sleep characteristics are shown in Fig. 3 (data shown in Supplementary Table S3). Lower severity of symptoms, except for cognition and anxiety, were positively associated with physical activity ($p < 0.05$). More severe breathlessness, fatigue, anxiety, depression, and post-traumatic stress disorder were all associated with greater sleep midpoint variability ($p < 0.01$). More severe depression was also associated with lower sleep efficiency ($p = 0.039$). Associations of physical performance with MVPA and intensity of the most active continuous 30/10 min were stronger in men than women ($p$ for interaction $< 0.05$) (Supplementary Table S3 and S4).

**Comparison to cohorts of office workers and those with type 2 diabetes**

Characteristics of the SMART Work and Life (SWL) ($n = 232$) and Chronotype of Patients with Type 2 Diabetes and Effect on Glycaemic Control (CODEC) ($n = 685$) comparator cohorts are shown in Supplementary Table S5 with differences in physical behaviours shown in Supplementary Table S6. Mean age was within five years of the PHOSP-COVID cohort for both comparator cohorts, while the CODEC cohort was well-matched for key characteristics including sex, multimorbidity status and BMI. Overall, activity was higher in the SWL and CODEC cohorts compared to PHOSP-COVID, with notably higher activity in the SWL cohort. The differences in activity volume of 1.1 mg in CODEC and 3.2 mg in SWL. Those in PHOSP-COVID spent ~ 17 fewer minutes in light-intensity activity than those in CODEC ($p = 0.004$) and ~ 16 fewer minutes in MVPA ($p < 0.001$) than those in SWL, with men also spending more time inactive compared to CODEC ($p = 0.020$). The intensity of the most active 30/10 min was also lowest in PHOSP-COVID ($p < 0.001$). The frequency of continuous bouts of
Table 3  Physical activity and sleep variables across four recovery clusters

| Physical activity variables | Women                                      | Men                                      | P for class | P for class x sex |
|-----------------------------|--------------------------------------------|------------------------------------------|-------------|------------------|
| Cluster 4: Mild             | Cluster 3: Moderate                        | Cluster 2: Severe                        | Cluster 1: Very Severe | Cluster 3: Moderate | Cluster 2: Severe | Cluster 1: Very Severe |
| Physical activity volume (mg) | 21.5 (19.5, 23.6)                           | 22.2 (19.5, 24.9)                       | 19.3 (16.9, 21.8) | 20.6 (18.1, 23.1) | 22.3 (20.6, 24.1) | 22.3 (20.6, 24.1) |
| Moderate to vigorous intensity physical activity (minutes/day) | 19.2 (13.0, 25.4)                           | 18.0 (10.3, 26.4)                       | 16.0 (8.8, 23.3) | 16.8 (9.2, 24.3) | 29.3 (24.1, 34.5) | 26.7 (20.3, 33.1) |
| Light intensity physical activity (minutes/day) | 164.8 (149.6, 180.1)                       | 168.2 (148.4, 187.9)                    | 145.2 (127.4, 163.0) | 156.3 (137.9, 174.7) | 148.1 (135.4, 160.8) | 153.2 (137.5, 168.9) |
| Inactivity (hours/day)     | 12.2 (11.7, 12.7)                           | 11.9 (11.3, 12.6)                       | 12.5 (12.0, 13.1) | 12.5 (11.9, 13.1) | 12.8 (12.4, 13.2) | 12.8 (12.2, 13.3) |
| Intensity of the most active continuous 30 min (mg) | 56.2 (41.9, 70.5)                           | 59.6 (41.2, 78.1)                       | 53.0 (36.3, 69.8) | 45.2 (27.9, 62.4) | 70.4 (58.4, 82.4) | 69.29 (54.5, 84.1) |
| Intensity of the most active continuous 10 min (mg) | 86.1 (66.6, 105.6)                           | 84.6 (59.4, 109.7)                      | 78.2 (55.3, 101.0) | 67.0 (43.5, 90.56) | 1046 (883, 1210) | 97.43 (77.3, 117.6) |
| Sleep variables             |                                            |                                          |             |                  |                  |                  |
| Total sleep time (hours/day) | 7.0 (6.6, 7.3)                              | 6.8 (6.4, 7.2)                          | 7.2 (6.8, 7.6) | 6.8 (6.4, 7.3) | 6.5 (6.2, 6.8) | 6.4 (6.1, 6.8) |
| Sleep efficiency (%)        | 85.9 (84.2, 87.6)                           | 85.1 (82.9, 87.3)                       | 87.3 (85.2, 89.5) | 86.7 (84.6, 88.7) | 85.6 (84.2, 87.1) | 84.6 (82.8, 86.3) |
| Sleep midpoint variability (minutes) | 92.4 (66.3, 87.6)                           | 95.3 (61.1, 87.3)                       | 74.5 (43.7, 89.3) | 1120 (803, 887) | 87.4 (65.6, 87.1) | 97.8 (70.7, 86.3) |

Data reported as marginal mean (95% CI). Adjusted for age, sex, ethnicity, deprivation, number of comorbidities, season of data collection and number of wear days (physical activity variables) or wear nights (sleep variables). Models included 490 participants with complete cluster and covariate data.
MVPA/week in PHOSP-COVID was similar to CODEC, but notably lower compared to SWL (p < 0.001) (Supplementary Figure S4). The variability in sleep midpoint was at least three times greater in PHOSP-COVID compared to SWL and CODEC (p < 0.001), with sleep efficiency also lower (p < 0.001) being 83.5% [95%CI 82.3, 84.7] in women and 82.7% [95%CI 81.6, 83.9] in men, but ≥86.5% in SWL and CODEC. Total sleep time was similar across the three cohorts (p > 0.092).

**Discussion**

Women and men recovering from a hospital admission for COVID-19 had low levels of physical activity and high variability in sleep timing. More severe acute illness was associated with approximately 1–2 mg lower volume of physical activity (approximating 500–1000 fewer steps per day) [18] and fewer minutes accumulated in MVPA, whereas more severe recovery clusters were associated with a low frequency of continuous sessions of physical activity per week, longer total sleep time and high variability in sleep timing. Further, the physical activity and sleep profile were notably worse in the PHOSP-COVID cohort than a similarly aged office worker comparator cohort [15], with the 3.2 mg difference in activity volume approximating 1600 fewer steps per day [18]. Relative to our well-matched comparator group with type 2 diabetes [17], differences in activity volume approximated 550 fewer steps per day [18], approximately 17 fewer minutes spent in light-intensity activity, with three times higher variability in sleep timing and lower sleep efficiency.

Among COVID-19 sufferers, sleep disturbance is one of the most commonly reported symptoms, irrespective of acute illness severity, and is highly prevalent following hospital discharge [19]. Irregular sleep patterns as observed in this cohort, independent of total sleep time, can lead to circadian disruption which is a risk factor for metabolic syndrome, obesity, dyslipidemia, and diabetes [20].

Being inactive, defined as not meeting the physical activity guidelines of 150 min of MVPA per week [21], is a risk factor for acute COVID-19 severity, with those who are inactive being 2.26 times more likely to be admitted to hospital, 1.73 times more likely to need intensive care,
and 2.49 times more likely to die [4]. Given this, and that habitual physical activity is generally fairly stable [22], it is possible that the lower physical activity in those with more severe acute COVID-19 may reflect their activity levels prior to infection with COVID-19.

The recovery clusters in PHOSP-COVID are not closely associated with acute illness severity [3], consistent with previous research [23]. Thus, the differences observed in continuous bouts of physical activity and sleep across recovery clusters likely reflect the participants’ current mental and physical health impairment. This suggests that the ability to sustain a 10- or 30-min session of activity without resting is compromised in those with more severe ongoing symptoms. Further, the sleep routine appears to be disrupted across all participants within the dataset, but particularly in those
in the more severe cluster. Both behaviours are associated with the multiple impairments that characterise the more severe clusters [3], including anxiety and depression [24–26], fatigue [27], and physical function [28]. These data suggest that rehabilitation pathways that have been set up to manage recovery from COVID-19 should focus on the spectrum of behaviours that encompass the 24-h period, including facilitating a return to normal patterns of physical activity, including being able to undertake longer bouts of physical activity, along with focusing on addressing sleep disruption issues.

Strengths and limitations
Key strengths of this study are its size, the comprehensively phenotyped multicentre cohort with novel clinical phenotypes, and accelerometer-assessed physical behaviours at scale. Irrespective, the study has several limitations. Notably, it was not possible to obtain measures of physical behaviours for the participants before they were infected with COVID-19. To account for this, we compared the data to a similarly aged cohort of office workers [15] and a cohort of adults with type 2 diabetes who were well-matched on key characteristics including sex, multimorbidity status, and BMI [17]. However, the data were collected on the comparator cohorts prior to the pandemic; we acknowledge that patterns of physical behaviours may also have been impacted due to the COVID-19 restrictions that have been imposed in the UK (and worldwide) to limit the spread of the virus. Variability in sleep timing and sleep efficiency were the main differences between the PHOSP-COVID and comparator cohorts in the present study. We have previously shown that these sleep-related variables did not differ before and during COVID-19 restrictions, suggesting the differences observed are unlikely due to differences in the measurement period [29]. Due to missing patient-reported outcome data within the PHOSP-COVID cohort, a cluster assignment was not derived for all participants. Finally, over 66% of the cohort had valid accelerometer data but those with data tended to be older, from less deprived communities, and with a lower proportion from ethnic minority communities. Therefore, the data presented may not be generalizable to all those recovering from a hospital admission for COVID-19. Although we used data from a well-phenotyped cohort of patients recovering from a hospital admission for COVID-19, it is not possible to disentangle to what extent these results are specific to COVID-19 or reflect recovery from acute illness requiring hospitalisation more generally.

Conclusions
Survivors of a hospital admission for COVID-19 have low levels of physical activity and significantly disrupted patterns of sleep several months after discharge. Acute illness severity was associated with lower total and moderate-to-vigorous activity following discharge, whereas more severe recovery clusters were associated with substantially fewer bouts of continuous physical activity and greater variability in sleep timing. Without modification, these behaviours are likely to result in further future disease. Physical activity, particularly sustained continuous bouts, and variability in sleep timing are potential treatable traits for survivors of COVID-19.

Acknowledgements
This study would not be possible without all the participants who have given their time and support. We thank all the participants and their families. We thank the many research administrators, health-care and social-care professionals who contributed to setting up and delivering the study at all of the 65 NHS trusts/Health boards and 25 research institutions across the UK, as well as all the supporting staff at the NIHR Clinical Research Network, Health Research Authority, Research Ethics Committee, Department of Health and Social Care, Public Health Scotland, and Public Health England, and support from the ISARC Coronavirus Clinical Characterisation Consortium. We thank Kate Holmes at the NIHR Office for Clinical Research Infrastructure (NOCR) for her support in coordinating the charities group. The PHOSP-COVID industry framework was formed to provide advice and support in commercial discussions, and we thank the Association of the British Pharmaceutical Industry as well as Ivana Poparic and Peter Sargent at NOCR for coordinating this. We are very grateful to all the charities that have provided insight to the study: Action Pulmonary Fibrosis, Alzheimer’s Research UK, Asthma UK/British Lung Foundation, British Heart Foundation, Diabetes UK, Cystic Fibrosis Trust, Kidney Research UK, MQ Mental Health, Muscular Dystrophy UK, Stroke Association, Blood Cancer UK, McPin Foundations, and Versus Arthritis. We thank the NIHR Leicester Biomedical Research Centre patient and public involvement group and the Long Covid Support Group. Details of the PHOSP-COVID Collaborative Group membership is provided as a supplementary file.

Authors’ contributions
The manuscript was initially drafted by TP, TY, AVR, and further developed by the writing committee. TY, AVR, CLE, TP made substantial contributions to the conception and design of the work. TP, CLE, TP, AVR, RAE, AS, MS, RMS, VCH, CEBo, JDC, DGW, L-PH, AH, MM, WD-CM made substantial contributions to the acquisition of data. TY, AV, TP, CLE, RAE, MJU made contributions to the analysis or interpretation of data for the work. TY, AVR, TP verified the underlying data.
All authors contributed to data interpretation and critical review and revision of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. The author(s) read and approved the final manuscript.

**Funding**

Jointly funded by UK Research and Innovation and National Institute of Health Research (grant references: MR/V027859/1 and COV0319). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Availability of data and materials**

The protocol, consent form, definition and derivation of clinical characteristics and outcomes, training materials, regulatory documents, information about requests for data access, and other relevant study materials are available online https://www.ph osp.org.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the Leeds West Research Ethics Committee (20/YH/0225). All study participants provided written informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

CEBo reports grants from NUH Trust RfB / NIHR Nottingham BRC and Nottingham Hospital Charity, outside of the submitted work. SAG reports grants from NIHR clinical lectureship and Kidney Beam Trial funded by Kidney Research UK and being a member of global steering committee of the MIFT trial (Australia) and President UK Kidney Association, Joint Chair UK Kidney Research Consortium, outside of the submitted work. WD‑CM reports grants from National Institute for Health Research and British Lung Foundation, personal fees from Mundipharma, Novartis, and European Conference and Incentive Services DMc, and being an advisory board member for Jazz Pharmaceuticals, outside of the submitted work. CMN reports being Co‑chair of British Thoracic Society Pulmonary Rehabilitation Group, outside of the submitted work. JW reports grants from NIHR Programme Development Grant 2021 — Digital and Remote Enhancements for the Assessment and Management of older people living with frailty, and King’s College Hospital Charity 2020 — COVID‑19 rehabilitation scoping work, outside of the submitted work. LHW reports grants from NIHR RPB and ARC East Midlands, outside of the submitted work. JOC reports grants from Astrazeneca, Boehringer Ingelheim, Novartis, Gilead Sciences, Insmed, Glaxosmithkline, and fees for consultancy from Astrazeneca, Boehringer Ingelheim, Novartis, Zambon, Gilead Sciences, Insmed, Glaxosmithkline, Chesi, outside of the submitted work. LPH reports grants from UKRF for UKILD study, MRC UK Regenerative Medicine Platform, Celgene (Immune mechanisms in fibrosis), British Lung Foundation (Immune drivers in Sarcoidosis), Boehringer‑Ingelheim (IPF study), reports being on advisory board for CASTALYST, phase 2 COVID platform trial and Chair of Respiratory Translational Research Collaboration, outside of the submitted work. AH reports grants from NIHR Manchester Biomedical Research Centre, during the conduct of the study and reports being Deputy Chair NIHR Translational Research Collaboration, outside of the submitted work. BR reports grants from British Heart Foundation Oxford Centre of Research Excellence, NIHR Oxford BRC and UKRF MRC during the conduct of the study, and fees for consultancy from Ascella Therapeutics, and payment from Ascella Therapeutics, outside of the submitted work. LVW reports grants from GSK and Orion Pharma, fees for consultancy from Galapagos, personal fees from Genentech, and being on advisory board for Galapagos, outside of the submitted work. RAE reports grants from NIH, personal fees from Boehringer and Chiesi, and being European Respiratory Society Assembly 01.02 Pulmonary Rehabilitation secretary, outside of the submitted work. MID is co‑funded by the NIHR Leicester Biomedical Research Centre. TV reports grants from NIHR Leicester BRC during the conduct of the study, and grants from UKRF (MRC)‑DHSC (NIHR) COVID19 Rapid Response Rolling Call (MR/V020536/1) and from HDR‑UK (HDRUK2020.138), outside of the submitted work. KK reports being Chair of the Ethnicity Subgroup of the UK Scientific Advisory Group for Emergencies (SAGE). DGW is supported by an NIHR Advanced Fellowship. CEB reports grants from Grants from GSK, AZ, Sanofi, BI, Chiesi, Novartis, Roche, Genentech, Mologic, 4DPharma, fees to institution for consultancy GSK, AZ, Sanofi, BI, Chiesi, Novartis, Roche, Genentech, Mologic, 4DPharma, TEVA. All other authors declare no competing interests.

**Author details**

1 Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester LE5 4PW, UK. 2 NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK. 3 NIHR Leicester Biomedical Research Centre, The Institute for Lung Health, University of Leicester, Leicester, UK. 4 University Hospitals of Leicester NHS Trust, Leicester, UK. 5 School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK. 6 University of Nottingham, Nottingham, UK. 7 Nottingham University Hospitals NHS Trust, Nottingham, UK. 8 University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. 9 Department of Respiratory Sciences, University of Leicester, Leicester, UK. 10 Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK. 11 Department of Physiotherapy and Renal Medicine, King’s College Hospital, London, UK. 12 Department of Renal Medicine, King’s College London, London, UK. 13 Department of Health Sciences, University of Leicester, Leicester, UK. 14 MRC Human Immunology Unit, University of Oxford, Oxford, UK. 15 NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 16 Division of Infection, Immunity & Respiratory Medicine, Faculty of Medico, Biology and Health, University of Manchester, Manchester, UK. 17 Manchester University NHS Foundation Trust, Manchester, UK. 18 Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK. 19 Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK. 20 Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. 21 Hospital for Tropical Diseases, University College London Hospital, London, UK. 22 Harefield Respiratory Research Group, Royal Brompton and Harefield Clinical Group, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. 23 College of Health, Medicine and Life Sciences, Department of Health Sciences, Brunel University London, Uxbridge, UK. 24 Asthma UK and British Lung Foundation, London, UK. 25 NHII, Imperial College London, London, UK. 26 Radcliffe Department of Medicine, University of Oxford, Oxford, UK. 27 Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 28 College of Life Sciences, University of Leicester, Leicester, UK. 29 School of Life Course & Population Sciences, King’s College London, London, UK. 30 Department of Clinical Gerontology, King’s College Hospital, London, UK. 31 Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. 32 Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. 33 Royal Brompton and Harefield Clinical Group, Guys and St Thomas’ NHS Foundation Trust, London, UK. 34 National Heart and Lung Institute, Imperial College London, London, UK.

Received: 25 February 2022   Accepted: 6 July 2022

Published online: 28 July 2022

**References**

1. World Health Organisation. WHO Coronavirus (COVID‑19) Dashboard. https://covid19.who.int/ (Accessed 21/01/2022).

2. Public Health England. Coronavirus (COVID‑19) in the UK. https://coronavirus.data.gov.uk/ (Accessed 21/01/2022).

3. Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical, cognitive, and mental health impacts of COVID‑19 after hospitalisation (PHOSP‑COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275–87.

4. Sallis R, Young DR, Tartof SY, Sallis JF, Sall J, Li Q, et al. Physical inactivity is associated with a higher risk for severe COVID‑19 outcomes: a study in 48 440 adult patients. Br J Sports Med. 2021;55:1099–105.

5. Rowlands AV, Koecker DE, Chutsasma Y, Davies MJ, Danksins NP, Edwardson CL, et al. Association of balance and timing of physical activity and rest with risk of COVID‑19 in UK Biobank. Mayo Clin Proc. 2021;96:156–64.

6. Sallis JF, Adlakha D, Oyeleyemi A, Salvo D. An international physical activity and public health research agenda to inform coronavirus disease‑2019 policies and practices. J Sport Health Sci. 2020;9:328–34.

7. Vepa A, Bae JP, Ahmed F, Paneek M, Khunti K. COVID‑19 and ethnicity: a novel pathophysiological role for inflammation. Diabetes Metab Syn Clin Res. 2020;14(5):1043–5.
8. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.
9. Chastin S, Abaraoju U, Bourgois JG, Dall PM, Dambourough J, Duncan E, et al. Effects of regular physical activity on the immune system, vaccination and risk of community-acquired infectious disease in the general population: systematic review and meta-analysis. Sports Med. 2021;51:16–73–1686.
10. Migueles JH, Rowlands AV, Hubler F, Sabia S, van Hees VT. GGIR: a research community-driven open-source R-package for generating physical activity and sleep outcomes from multi-day raw accelerometer data. J Measure Phys Behav. 2019;2:188–96.
11. Hildebrand M, van Hees VT, Hansen BH, Bkelund U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc. 2014;46:1816–24.
12. Hildebrand M, Hansen BH, van Hees VT, Bkelund U. Evaluation of raw acceleration sedentary thresholds in children and adults. Scand J Med Sci Sports. 2017;27:1814–23.
13. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The physical activity guidelines for Americans. JAMA. 2018;320(19):2020–8.
14. Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–7.
15. Edwardson CL, Biddle SJ, Clarke-Cornwell A, Clesmes S, Davies MJ, Dunstan DW, et al. A three-arm cluster randomised controlled trial to test the effectiveness and cost-effectiveness of the SMART Work & Life intervention for reducing daily sitting time in office workers: study protocol. BMC Public Health. 2018;18(1):1–3.
16. Brady EM, Hall AP, Baldry E, Charterjee S, Daniels LJ, Edwardson CL, et al. Rationale and design of a cross-sectional study to investigate and describe the chronotype of patients with type 2 diabetes and the effect on glycaemic control: the CODEC study. BMJ Open. 2019;9:e027773.
17. Henson J, Rowlands AV, Edwardson CL, Brady EM, Davies MJ, Edwardson CL, et al. Physical behaviours and chronotype in people with Type 2 diabetes. BMJ Open Diabetes Res Care. 2020;8:e001375.
18. Rowlands AV, Davies MJ, Dempsey PC, Edwardson C, Razieh C, Yates T. Wrist-worn accelerometers: Recommending ~1.0 mg as the minimum clinically important difference (MCID) in daily average acceleration for inactive adults. Br J Sports Med. 2021;55:814–518.
19. Lin YN, Liu ZR, Li SQ, Li CX, Zhang L, Li N, et al. Burden of sleep disturbance during COVID-19 pandemic: a systematic review. Nat Sci Sleep. 2021;13:933–66.
20. Zuraikat FM, Makaren N, Redline S, Aggarwal B, Jelic S, St-Onge MP. Sleep regularity and cardiometabolic health: is variability in sleep patterns a risk factor for excess adiposity and glycemc dysregulation? Curr Diab Rep. 2020;20:38.
21. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Brit J Sports Med. 2020;54:1451–62.
22. Friedman HS, Martin LR, Tucker JS, Criqui MH, Kern ML, Reynolds CA. Stability of physical activity across the lifespan. J Health Psychol. 2008;13(8):1092–1104.
23. Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28–33.
24. Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019;23(4):2324–32.
25. McDowell CP, Dishman RK, Gordon BR, Herring MP. Physical activity and anxiety: a systematic review and meta-analysis of prospective cohort studies. Am J Prev Med. 2019;57(4):545–56.
26. Schuch FB, Vancampfort D, Firth J, Rosenbaum S, Ward PB, Silva ES, et al. Physical activity and incident depression: a meta-analysis of prospective cohort studies. Am J Psychiatry. 2018;175(7):631–48.
27. Zaslavsky O, Su Y, Rillamas-Sun E, Roopswanig L, LaCroix AZ. Accelerometer-Measured Physical Activity Levels and Fatigue in Older Women. J Aging Phys Act. 2020;28(5):692–8.
28. Mickute M, Henson J, Rowlands AV, Sargeant JA, Webb D, Hall A, et al. Device-measured physical activity and its association with physical function in adults with type 2 diabetes mellitus. Diabet Med. 2020;38(6):e14393.
29. Rowlands AV, Henson J, Coull NA, Edwardson CL, Brady E, Hall A, et al. The impact of COVID-19 restrictions on accelerometer-assessed physical activity and sleep in individuals with type 2 diabetes. Diabet Med. 2021;38(10):e14549.